Ergoteles’s Seres Therapeutics MCRB Stock Holding History

Ergoteles’s Portfolio MCRB Stock Details MCRB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,384	Closed	-$267K	–	1553
2022 Q4	$267K	Buy	+2,384	New	+$320K	0.01%	956
2022 Q3	–	Sell	-3,627	Closed	-$249K	–	1797
2022 Q2	$249K	Buy	+3,627	New	+$312K	0.01%	1205

Other funds holding MCRB

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Ergoteles's MCRB Position: Q1 2023 in Review

Ergoteles sold out of Seres Therapeutics (MCRB) in Q1 2023, closing a stake of 2,384 shares — an estimated $267K sold.

Ergoteles first reported a position in MCRB in Q2 2022 and held it in 2 quarters. The position peaked at $267K in Q4 2022. 123 funds tracked by Wall St. Rank hold MCRB as of Q1 2023.

Ergoteles reported no remaining Seres Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 2,384 Seres Therapeutics shares in Q1 2023, an estimated $267K.
Ergoteles first reported a position in Seres Therapeutics in Q2 2022 and held it in 2 quarters.
Ergoteles's Seres Therapeutics position peaked at $267K in Q4 2022.
123 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.